R&D channel feed – Endpoints News

R&D channel feed

Biogen plans to open new headquarters in Boston area in 2028

Last month

AstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China

Last month

CDC vaccine meeting, delayed earlier this year, is rescheduled

Last month

Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'

Last month

Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis

Last month

Cargo Therapeutics scraps R&D pipeline, axes bulk of workforce as it looks for an exit

Last month

Regenxbio shares new Duchenne gene therapy data ahead of big readout next year

Last month

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win

Last month

Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets

Last month

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Last month

CRISPR company Arbor raises $73.9M to test therapy in clinical trials

Last month

AstraZeneca reports Phase 3 success for rare disease drug at heart of Amolyt deal

Last month

Incyte's stock sinks as pivotal skin disease data disappoint

Last month

Orca Bio's T cell therapy may help blood cancer patients avoid transplant issues

Last month

George Church spinout developing genomically recoded organisms cuts most employees

Last month

AstraZeneca spotlights first-in-human data for B7-H4-targeting ADC in endometrial cancer

Last month

Avidity seeks to 'set the standard' as it heads to FDA with Duchenne drug

Last month

Boston Pharma, building off MASH momentum, mulls an IPO ahead of Phase 3 trial

Last month

Pfizer terminates an early-stage STING agonist trial

Last month

Amgen reports more Uplizna data in myasthenia gravis ahead of FDA filing

Last month

#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatment

Last month

Ono licenses rare blood disease drug from Ionis for $280M upfront

Last month

Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B

Last month

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

2 months ago

First page Previous page 3 4 567 8 9 Next page Last page